Different natural courses of chronic hepatitis B with genotypes B and C after the fourth decade of life

Maeshiro, Tatsuji; Arakaki, Shingo; Watanabe, Tomonori; Aoyama, Hideyasu; Shiroma, Joji; Yamashiro, Tsuyoshi; Hirata, Tetsuo; Hokama, Akira; Kinjo, Fukunori; Nakayoshi, Tomofumi; Nakayoshi, Tomokuni; Mizokami, Masashi; Fujita, Jiro; Sakugawa, Hiroshi

doi:10.3748/wjg.v13.i34.4560

Cited by 11 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An estimated 20z to 30z of HBsAg carriers may experience reactivation of hepatitis B with elevation of biochemical levels and high serum DNA levels with or without seroconversion to HBeAg. HBV reactivation is usually asymptomatic, but it may mimic active viral hepatitis (20,26,27).…”

Section: -1 Clinical Differences Of Hbv Genotypesmentioning

confidence: 99%

Correlation between Hepatitis B Virus Genotypes and Clinical Outcomes

Shi¹

2012

Jpn J Infect Dis

View full text Add to dashboard Cite

Section: -1 Clinical Differences Of Hbv Genotypesmentioning

confidence: 99%

Correlation between Hepatitis B Virus Genotypes and Clinical Outcomes

Shi¹

2012

Jpn J Infect Dis

View full text Add to dashboard Cite

“…Older age at presentation and not knowing the duration of exposure jointly suggests late presentation of CHB patients at the study site hospital. The course of hepatitis B after the fourth decade of life is more severe and associated with a higher chance of cirrhosis and cancer [22]. Therefore, community awareness should be raised about the treatment of CHB to prevent liver cancer.…”

Section: Discussionmentioning

confidence: 99%

Observation of genotype C infected chronic hepatitis B patients in clinical practice

Aung

Leowattana

Tangpukdee

et al. 2011

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Hepatitis B virus (HBV) genotype C is prevalent in many areas of the world including Thailand and Southeast Asia. It is a strong risk for hepatocellular carcinoma (HCC) by evidence. We aimed to describe the baseline clinical information of treatment naïve genotype C infected chronic hepatitis B (CHB) patients and to describe the treatment response by surrogate outcome markers in genotype C infected CHB patients after one year of nucleos(t)ide analogues (NA) treatment Methodology: Thirty-four genotype C CHB patients were studied at the Hospital for Tropical Diseases, Bangkok, including 12 patients treated with lamivudine, 11 with telbivudine, 8 with adefovir, and 3 with entecavir. Serum HBV DNA levels, serum alanine amino transferase ( ALT ) levels, HBeAg status, and alpha-feto protein (AFP) levels were recorded at the start and after twelve months of ongoing treatment. HBV genotyping was performed by line-probe assay. Results: About half of the patients (58.8%) were HBeAg positive. Mean HBV viral load was 6.53 + 1.15 log10 copies per ml at baseline and reduced to 3.63 + 1.3 log10 copies per ml after one year of NA treatment. Serum HBV DNA levels became undetectable in 47.1 % of the patients and serum ALT was normalized in 23.5 % of the patients. Conclusion: Most of the genotype C patients were aged above 40 years. More than half of the genotype C infected patients did not achieve virological response and biochemical remission. Among the CHB patients, genotype C infected patients are a high priority group for intervention.

show abstract

“…В процессе исследований последних лет открыто 8 генотипов HBV (от «А» до «Н»), которые влияют на клиническое течение болезни и эффективность противовирусной терапии [20,30,43]. Так, при лечении препаратами интерферона альфа больных хроническим ВГВ положительный вирусологический ответ чаще отмечают у больных с генотипами А и В (до 40%), реже -при генотипе D (до 10%).…”

unclassified

Modern aspects of the natural course of chronic viral hepatitis B

Enaleeva

2012

Kazan Med J

View full text Add to dashboard Cite

Currently there are about 400 million people infected with the hepatitis B virus, including five million people - in Russia. A serious problem is the development of complications of chronic viral hepatitis’ - liver cirrhosis and hepatocellular carcinoma, from which eventually 20-35% of patients die. Undoubtedly, the outstanding science achievement of the XX century was the creation of a genetically engineered vaccine against hepatitis B. The pursued immunizations on a global scale has led to significant results - reduction of the number of cases of acute forms of viral hepatitis B, the frequency of formation of the chronic variant of the disease. Despite these successes, there remains the problem of prevention of the perinatal transmission path. Identified were the risk factors for neonatal infection, amongst which the most significant are the presence of the antigen of the hepatitis B virus, which is not a part of the Dane particles (HBEAg), and the level of viremia prior to delivery. The basis of prevention is an active-passive immunization, which helps prevent infection in infants in 90-95% of cases. Encouraging results (reduction in the risk of infant infection) were obtained in studies of antiviral therapy in the III trimester of pregnancy. The introduction of new molecular biological diagnostic methods (polymerase chain reaction) made it possible to determine the genetic material of the virus in serum and tissues, the presence of mutations and genetic variability of the virus. At present, identified are the factors that determine the progression of the disease, the efficacy of antiviral therapy. Identified are the new variants of the clinical course of viral hepatitis B, depending on the profile of the serological (antigen-antibody) markers. The latent course of viral hepatitis B deserves special attention. The serological feature of this variant is the presence of «isolated» antibodies and/or deoxyribonucleic acid of the virus, or the absence of all markers of hepatitis B. It is obvious that patients with a latent course of infection pose a real threat in spreading viral hepatitis B.

show abstract

Different natural courses of chronic hepatitis B with genotypes B and C after the fourth decade of life

Cited by 11 publications

References 29 publications

Correlation between Hepatitis B Virus Genotypes and Clinical Outcomes

Correlation between Hepatitis B Virus Genotypes and Clinical Outcomes

Observation of genotype C infected chronic hepatitis B patients in clinical practice

Modern aspects of the natural course of chronic viral hepatitis B

Contact Info

Product

Resources

About